Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma

References

• Dimopoulos MA, Terpos E. Myeloma. Ann. Oncol. 21( Suppl. 7), vii 143–150 (2010).
   Google Scholar
• Kastritis E, Zervas K, Symeonidis A et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 23(6), 1152–1157 (2009).
   PubMed Web of Science ®Google Scholar
• Harousseau JL. Ten years of improvement in the management of multiple myeloma: 2000–2010. Clin. Lymphoma Myeloma Leuk. 10(6), 424–442 (2010).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 7(8), 585–598 (2007).
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel PL. Many multiple myelomas: making more of the molecular mayhem. Hematology Am. Soc. Hematol. Educ. Program 2011, 344–353 (2011).
   Google Scholar
• Yang J, Yi Q. Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. Am. J. Blood Res. 1(1), 22–33 (2011).
   PubMedGoogle Scholar
• Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC. Monoclonal antibodies in the treatment of multiple myeloma. Br. J. Haematol. 154(6), 745–754 (2011).
   PubMed Web of Science ®Google Scholar
• Tai YT, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011, 924058 (2011).
   PubMedGoogle Scholar
• Alcindor T, Kimlinger T, Witzig TE. High expression of CD59 and CD55 on benign and malignant plasma cells. Leuk. Lymphoma 47(5), 919–921 (2006).
   PubMed Web of Science ®Google Scholar
• His ED, Steinle R, Balasa B et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 14(9), 2775–2784 (2008).
   PubMedGoogle Scholar
• Tai YT, Dillon M, Song W et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112(4), 1329–1337 (2008).
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Dillon M et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol. Cancer Ther. 8(9), 2616–2624 (2009).
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120(3), 552–559 (2012).
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30(16), 1953–1959 (2012).
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J. Clin. Oncol. 30(16), 1960–1965 (2012).
   PubMed Web of Science ®Google Scholar
• van der Veer, MS, de Weers M, van Kessel B et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96(2), 284–290 (2011).
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186(3), 1840–1848 (2011).
   PubMed Web of Science ®Google Scholar
• van der Veer MS, de Weers M, van Kessel B et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 1(10):e41 (2011).
   PubMed Web of Science ®Google Scholar
• Plesner T, Lokhorst H, Gimsing P et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - Data from a dose-escalation phase I/II study. In: 54th ASH Annual Meeting and Exposition. Atlanta, GA (2012).
   Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol. 140(1), 36–45 (2008).
   PubMed Web of Science ®Google Scholar
• Lundqvist A, Abrams SI, Schrump DS et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 66(14), 7317–7325 (2006).
   PubMed Web of Science ®Google Scholar
• Shi J, Tricot GJ, Garg TK et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 111(3), 1309–1317 (2008).
   PubMed Web of Science ®Google Scholar
• Hallett WH, Ames E, Motarjemi M et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J. Immunol. 180(1), 163–170 (2008).
   PubMed Web of Science ®Google Scholar
• Ames E, Hallett WH, Murphy WJ. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin. Exp. Immunol. 155(3), 504–513 (2009).
   PubMed Web of Science ®Google Scholar
• Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. FASEB J. 10(12), 1408–1417 (1996).
   PubMed Web of Science ®Google Scholar
• Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk. Res. 25(1), 1–12 (2001).
   PubMed Web of Science ®Google Scholar
• Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol. 121(4), 482–488 (2004).
   PubMed Web of Science ®Google Scholar
• Santonocito AM, Consoli U, Bagnato S et al. Flow cytometric detection of aneuploid CD38(++) plasma cells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk. Res. 28(5), 469–477 (2004).
   PubMed Web of Science ®Google Scholar
• Gallay N, Anani L, Lopez A, et al. The role of platelet/endothelial cell adhesion molecule 1 (CD31) and CD38 antigens in marrow microenvironmental retention of acute myelogenous leukemia cells. Cancer Res. 67(18), 8624–8632 (2007).
   PubMed Web of Science ®Google Scholar
• Partida-Sánchez S, Cockayne DA, Monard S et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat. Med. 7(11), 1209–1216 (2001).
   PubMedGoogle Scholar
• Lokhorst H, Plesner T, Gimsing P et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma – Data from the dose-escalation part of the FIH study. In: 2013 ASCO Annual Meeting, Chicago, IL (2013).
   Google Scholar
• Pellat-Deceunynck C, Bataille R, Robillard N et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 84(8), 2597–2603 (1994).
   PubMed Web of Science ®Google Scholar
• Harada H, Kawano MM, Huang N et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81(10), 2658–2663 (1993).
   PubMed Web of Science ®Google Scholar
• Burton JD, Ely S, Reddy PK et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin. Cancer Res. 10(19), 6606–6611 (2004)
   PubMed Web of Science ®Google Scholar
• Moreaux J, Hose D, Reme T et al. CD200 is a new prognostic factor in multiple myeloma. Blood 108(13), 4194–4197 (2006).
   PubMed Web of Science ®Google Scholar
• Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br. J. Haematol. 141(2), 135–148 (2008).
   PubMed Web of Science ®Google Scholar
• Zojer N, Kirchbacher, Vesely M, Hübl W, Ludwig H. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk. Lymphoma. 47(6), 1103–1109 (2006).
   PubMed Web of Science ®Google Scholar
• Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J. 14(4), 799–805 (2012).
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Wolf, J, Gharibo M et al. Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis. In: 51th ASH Annual Meeting and Exposition. New Orleans, LO (2009)
   Google Scholar
• Gay F, Larocca A, Wijermans P et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117(11), 3025–3031 (2011).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 114(15), 3139–3146 (2009).
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366(19), 1782–1791 (2012).
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366(19), 1770–1781 (2012).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N. Engl. J. Med. 366(19), 1759–1769 (2012).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Richardson PG, Brandenburg N et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 119(12), 2764–2767 (2012).
   PubMed Web of Science ®Google Scholar